Hi there,

If you think Democracy Now!’s reporting is a critical line of defense against war, climate catastrophe and authoritarianism, please make your donation of $10 or more right now. Today, a generous donor will DOUBLE your donation, which means it’ll go 2x as far to support our independent journalism. Democracy Now! is funded by you, and that’s why we’re counting on your donation to keep us going strong. Please give today. Every dollar makes a difference—in fact, gets doubled! Thank you so much.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.

Donate

British Drug Test Study Leaves 2 in Critical Condition

HeadlineMar 17, 2006

In Britain, two men are in critical condition after suffering violent reactions to a pill they took as part of a clinical study. Another four participants in the study are in serious condition. The study, run by American drug research company Parexel International, gave the participants doses of the German drug TGN 1412. Myfanwy Marshall, the partner of one of the hospitalized men, said: “His face is bloated out like 'elephant man'… it’s all the blood, they’re recycling his blood trying to clean it out, you know, it’s affected every organ, every… his kidneys, his lung, his liver, his heart his blood circulation, everything; and they’re just trying to keep that ticking over with their machines, so he’s on life support. And they’re telling me he could die at any moment.”

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation
Top